Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 17:13:1227864.
doi: 10.3389/fonc.2023.1227864. eCollection 2023.

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru

Yomali Ferreyra  1 , Gina Rosas  2 , Alicia M Cock-Rada  3 , Jhajaira Araujo  4 , Leny Bravo  5 , Franco Doimi  6 , Jhoysi Casas  6 , María de Los Ángeles Clavo  7 , Joseph A Pinto  4 , Carolina Belmar-López  5   6
Affiliations

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru

Yomali Ferreyra et al. Front Oncol. .

Abstract

Background: There is an increasing amount of data from Latin America on the characterization of BRCA variants; however, there is limited information from Peru. We conducted a retrospective study to describe germline pathogenic/likely pathogenic(P/LP) variants and variants of uncertain/unknown significance (VUS) in the BRCA1 and BRCA2 genes in Peru, in patients with breast and ovarian cancer, candidates for treatment with poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors.

Methods: The patients were evaluated during the period 2019-2021. Genomic DNA was isolated from peripheral blood samples and targeted sequencing was performed using the Ampliseq BRCA panel. Genetic variant interpretation was carried out in accordance with the recommendations of the American College of Medical Genetics and ClinVar. During this period, 525 patients (143 with breast cancer and 382 with ovarian cancer) were studied.

Results: We found that 14.7% (21/143) of breast cancer patients and 20.7% (79/382) of ovarian cancer patients were carriers of P/LP variants in BRCA1/2. The most frequent pathogenic variants detected in BRCA1 were c.2105dupT (BIC: 2224insT, n=12, 18.75%), c.68_69delAG (BIC: 185delAG, n=6, 9.38%), c.140G>T and c.815_824dupAGCCATGTGG (n=5, 7.81%), while in BRCA2 were c.8023A>G (n=6, 16.67%), c.6024dupG (BIC: 6252insG, n=4, 11.11%), and c.9235delG (BIC: 9463delG, n=3, 8.33%). Regarding VUS, we found that 6.99% (10/143) of breast cancer patients and 7.33% (28/382) of ovarian cancer patients were carriers of a VUS in BRCA1/2. For BRCA1, the most frequent VUS was c.93C>G (n=2), and for BRCA2, c.5465A>T (n=4), c.3101T>C (n=3), c.205C>A and c.437T>C (n=2).

Conclusion: We found a frequency of 14.7% germline mutations in breast cancer patients and 20.7% in ovarian cancer patients. The most recurrent mutations were BRCA1 c.2105dupT and BRCA2 c.8023A>G. We found that BRCA2 c.8023A>G, c.6024dupG, and c.9235delG were not previously reported in Peruvian patients. BRCA1 c.2344dupA is a novel mutation that has not been previously reported in any database. The frequency of VUS in our cohort was 7.2%.

Keywords: BRCA1; BRCA2; breast cancer; germline mutation; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart showing results and characteristics of patients with breast and ovarian cancer included in this study. P/LP, Pathogenic/likely pathogenic.
Figure 2
Figure 2
Pathogenic/likely pathogenic germline BRCA1/2 variants according to the place of birth (A) Germline BRCA1 LP/P variants (B) Germline BRCA2 LP/P variants.
Figure 3
Figure 3
Maps presenting counts of pathogenic and likely pathogenic variants sites in (A) Brca1 and (B) Brca2 proteins.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer (2021) 28(6):1167–80. doi: 10.1007/s12282-020-01148-2 - DOI - PMC - PubMed
    1. Saleem M, Ghazali MB, Wahab MAMA, Yusoff NM, Mahsin H, Seng CE, et al. The BRCA1 and BRCA2 genes in early-onset breast cancer patients. Adv Exp Med Biol (2020) 1292:1–12. doi: 10.1007/5584_2018_147 - DOI - PubMed
    1. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer (2022). GeneReviews®. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1247/ (Accessed cited 2023 Jul 11).
    1. Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res (2006) 66(16):8297–308. doi: 10.1158/0008-5472.CAN-06-0503 - DOI - PubMed